IPO Trending
SAIPARENTEQ / NSE, BSEListed

Sai Parenteral's Limited

Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical company engaged in the research, development, and manufacturing of formulations, operating across two main segments: branded generic formulations and contract development and manufacturing (CDMO) services for both domestic and international markets. Its product portfolio covers multiple therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology, with offerings available in various dosage forms including injectables, tablets, capsules, liquid orals, and ointments. The company serves a wide customer base including government agencies, pharmaceutical companies, hospitals, and distributors across India, and expanded into exports in FY 2023 after acquiring internationally accredited facilities in Hyderabad, enabling supply to markets like Australia, New Zealand, Southeast Asia, the Middle East, and Africa. Sai Parenteral's operates five manufacturing facilities in India, four in Hyderabad and one through its wholly owned subsidiary Revat Laboratories in Ongole, Andhra Pradesh, all equipped with GMP and global certifications, and as of August 31, 2025, the company had 277 full-time employees.

₹372 - ₹3921.08x sub
Listed Price400.00
Listing Gain+2.04%
TimelineBookbuilding IPO
Open2026-03-24
Close2026-03-27
Allotment2026-03-30
Listing2026-04-02

Quota Reservation Portions

AnchorPortion: 31,28,485 shares
30%
QIBPortion: 20,85,659 shares
20%
HNIPortion: 15,64,243 shares
15%
RetailPortion: 36,49,901 shares
35%

Minimum Application Bracket Matrix

Retail1 lots / 38 shares
₹14,896
sHNI14 lots / 532 shares
₹2,08,544
bHNI68 lots / 2,584 shares
₹10,12,928

About the Company

Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical company engaged in the research, development, and manufacturing of formulations, operating across two main segments: branded generic formulations and contract development and manufacturing (CDMO) services for both domestic and international markets. Its product portfolio covers multiple therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology, with offerings available in various dosage forms including injectables, tablets, capsules, liquid orals, and ointments. The company serves a wide customer base including government agencies, pharmaceutical companies, hospitals, and distributors across India, and expanded into exports in FY 2023 after acquiring internationally accredited facilities in Hyderabad, enabling supply to markets like Australia, New Zealand, Southeast Asia, the Middle East, and Africa. Sai Parenteral's operates five manufacturing facilities in India, four in Hyderabad and one through its wholly owned subsidiary Revat Laboratories in Ongole, Andhra Pradesh, all equipped with GMP and global certifications, and as of August 31, 2025, the company had 277 full-time employees.

Company Promoters

Anil Kumar KarusalaVijitha GorrepatiKarusala Aruna